Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Langer

Showing results (461-470 of 596) with videos related to

Pageof 60
Sort By:
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.
Operative Neurosurgery (Hagerstown, Md.)|March 20, 2018
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory EsthesioneuroblastomaJulia R Schneider, Deborah R Shatzkes, Stephen C Scharf, et al.
Molecular & Cellular Proteomics : MCP|July 22, 2009
A mediator of Rho-dependent invasion moonlights as a methionine salvage enzymeYukihito Kabuyama, Elizabeth S Litman, Paul D Templeton, et al.
JCO Precision Oncology|July 15, 2026
EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung CancerWilldragon Wang, Dylan G Scholes, Alex C Watts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerCorey J Langer, Kenneth J O'Byrne, Mark A Socinski, et al.
Journal of Fungi (Basel, Switzerland)|August 26, 2021
Highly Clonal Structure and Abundance of One Haplotype Characterise the <i>Diplodia sapinea</i> Populations in Europe and Western AsiaKalev Adamson, Marili Laas, Kathrin Blumenstein, et al.
JTO Clinical and Research Reports|April 21, 2025
Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of ImmunotherapyMargaret Stalker, Suzanne L Walker, Emily Lebow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
International Journal of Radiation Oncology, Biology, Physics|October 22, 2023
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint InhibitorsCole Friedes, Michelle Iocolano, Sang Ho Lee, et al.
Pageof 60

Showing results (461-470 of 596) with videos related to

Sort By:
Pageof 60
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.
Operative Neurosurgery (Hagerstown, Md.)|March 20, 2018
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory EsthesioneuroblastomaJulia R Schneider, Deborah R Shatzkes, Stephen C Scharf, et al.
Molecular & Cellular Proteomics : MCP|July 22, 2009
A mediator of Rho-dependent invasion moonlights as a methionine salvage enzymeYukihito Kabuyama, Elizabeth S Litman, Paul D Templeton, et al.
JCO Precision Oncology|July 15, 2026
EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung CancerWilldragon Wang, Dylan G Scholes, Alex C Watts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancerCorey J Langer, Kenneth J O'Byrne, Mark A Socinski, et al.
Journal of Fungi (Basel, Switzerland)|August 26, 2021
Highly Clonal Structure and Abundance of One Haplotype Characterise the <i>Diplodia sapinea</i> Populations in Europe and Western AsiaKalev Adamson, Marili Laas, Kathrin Blumenstein, et al.
JTO Clinical and Research Reports|April 21, 2025
Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of ImmunotherapyMargaret Stalker, Suzanne L Walker, Emily Lebow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.
International Journal of Radiation Oncology, Biology, Physics|October 22, 2023
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint InhibitorsCole Friedes, Michelle Iocolano, Sang Ho Lee, et al.
Pageof 60